Charnita Zeigler-Johnson was named associate director of community outreach and engagement at Fox Chase Cancer Center.
Joseph L. Kissil was named chair of the Molecular Oncology Department at Moffitt Cancer Center.
Moffitt Cancer Center was granted $3.7 million from NCI’s Connecting Underrepresented Populations to Clinical Trials U01 Grants Program. The five-year, $3.7 million grant will help the cancer center develop new digital tools and community outreach strategies to reach Black and Hispanic cancer patients and physicians in the Tampa Bay community.
Winship Cancer Institute of Emory University and the Cleveland Clinic was awarded more than $7.9 million by the NCI to support a new Radiation Oncology-Biology Integration Network center.
The American Cancer Society has approved funding for 89 new Extramural Discovery Science research grants totaling $54.3 million. The grants will fund investigators at 65 institutions across the U.S. starting Jan. 1, 2023.
New research indicates that among individuals with breast cancer, those with a rare subtype called inflammatory breast cancer face a higher risk that their cancer will metastasize to the brain.
Allogene Therapeutics Inc., a clinical-stage biotechnology company, has initiated the first phase II clinical trial of allogeneic CAR T-cell therapy.
Female cancer patients are less satisfied with the quality of their cancer care than male cancer patients, and are more likely to report that their symptoms were not taken seriously and that they had to prove their symptoms to providers.
In a research paper published in PLOS ONE, Dario C. Altieri, president and chief executive officer, director of the Ellen and Ronald Caplan Cancer Center, and the Robert and Penny Fox Distinguished Professor at The Wistar Institute, alongside national and international collaborators, distinguish a specific gene signature indicative of mitochondrial reprogramming in tumors that correlates with poor patient outcome.
Health Canada has granted approval for Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as monotherapy for the adjuvant treatment of adults with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
